Published in Antivir Ther on January 01, 2007
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Antiviral resistance and hepatitis B therapy. Hepatology (2009) 1.67
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Nonpolar nucleoside mimics as active substrates for human thymidine kinases. J Am Chem Soc (2009) 1.00
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2008) 0.99
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep (2011) 0.99
Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol (2012) 0.99
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother (2012) 0.97
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One (2013) 0.97
Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver (2013) 0.95
Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol (2013) 0.94
Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med (2014) 0.94
Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology (2009) 0.92
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol (2014) 0.85
Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol (2014) 0.84
Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied? Antivir Ther (2010) 0.84
High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. Korean J Hepatol (2012) 0.84
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. Clin Mol Hepatol (2017) 0.84
Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag (2009) 0.82
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol (2012) 0.81
Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol (2010) 0.80
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. Drug Des Devel Ther (2014) 0.80
Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates. World J Gastroenterol (2014) 0.79
Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone. Saudi J Gastroenterol (2016) 0.79
Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells. World J Gastroenterol (2008) 0.77
Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B? Korean J Intern Med (2014) 0.77
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. Antimicrob Agents Chemother (2013) 0.76
New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist (2009) 0.76
The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol (2014) 0.76
Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver (2017) 0.75
Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study. Chin Med J (Engl) (2017) 0.75
Review of tenofovir-emtricitabine. Ther Clin Risk Manag (2007) 0.75
Effect and mechanism of beta-L-D4A on DNA polymerase alpha. World J Gastroenterol (2007) 0.75
Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. Virol J (2011) 0.75
Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol (2016) 0.75
High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. Dig Dis Sci (2011) 0.75
Design and implementation of microarray gene expression markup language (MAGE-ML). Genome Biol (2002) 16.75
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB. BMC Bioinformatics (2006) 7.53
Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA (2002) 6.48
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Pattern separation in the human hippocampal CA3 and dentate gyrus. Science (2008) 5.56
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat Biotechnol (2007) 3.55
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv (2007) 3.38
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 2.80
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Organizational Readiness for Change and opinions toward treatment innovations. J Subst Abuse Treat (2007) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction (2002) 1.94
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis (2007) 1.93
Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol (2003) 1.87
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol (2003) 1.80
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Image-based estimation of ventricular fiber orientations for personalized modeling of cardiac electrophysiology. IEEE Trans Med Imaging (2012) 1.72
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64
A chloroplast transgenic approach to hyper-express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol J (2003) 1.64
Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med (2010) 1.64
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63
Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther (2003) 1.63
Rising national prevalence of life-limiting conditions in children in England. Pediatrics (2012) 1.59
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant (2008) 1.52
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle (2012) 1.50
ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis (2002) 1.49
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (2013) 1.48
Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res (2006) 1.47
Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology (2011) 1.46
Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA (2012) 1.45
The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med (Berl) (2006) 1.42
Resistance to chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol (2007) 1.41
FuGE: Functional Genomics Experiment Object Model. OMICS (2006) 1.39
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36
The Oak Ridge Polycystic Kidney mouse: modeling ciliopathies of mice and men. Dev Dyn (2008) 1.36
Does glycemic variability impact mood and quality of life? Diabetes Technol Ther (2012) 1.35
Lead toxicity in a 14-year-old female with retained bullet fragments. Pediatrics (2006) 1.34
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis (2013) 1.31
Chromosomal location plays a role in regulation of aflatoxin gene expression in Aspergillus parasiticus. Appl Environ Microbiol (2002) 1.31
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology (2003) 1.31
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29
Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther (2007) 1.28
Annotare--a tool for annotating high-throughput biomedical investigations and resulting data. Bioinformatics (2010) 1.26
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther (2005) 1.25
Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology (2012) 1.25
Brief strategic family therapy versus treatment as usual: results of a multisite randomized trial for substance using adolescents. J Consult Clin Psychol (2011) 1.23
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2011) 1.23
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology (2003) 1.21
Long-term user perceptions of an implanted neuroprosthesis for exercise, standing, and transfers after spinal cord injury. J Rehabil Res Dev (2003) 1.19
Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP). Drug Alcohol Depend (2003) 1.19
Mindfulness meditation for alcohol relapse prevention: a feasibility pilot study. J Addict Med (2008) 1.18
Ethyl glucuronide: a biomarker to identify alcohol use by health professionals recovering from substance use disorders. Alcohol Alcohol (2004) 1.17
Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob Agents Chemother (2010) 1.17
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology (2003) 1.16
The use of social-networking sites in medical education. Med Teach (2013) 1.16
A randomised controlled 8-week crossover clinical evaluation of the 3M Coban 2 Layer Compression System versus Profore to evaluate the product performance in patients with venous leg ulcers. Int Wound J (2008) 1.15
Bath salts as a "legal high". Am J Med (2011) 1.15
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther (2004) 1.14
Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J (2012) 1.12
CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle (2012) 1.12
Tailoring cannabis dependence treatment for a diverse population. Addiction (2002) 1.12
Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer (2010) 1.11
Progressive resistance training after stroke: effects on muscle strength, muscle tone, gait performance and perceived participation. J Rehabil Med (2008) 1.11
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology (2002) 1.11
HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle (2012) 1.11
Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab (2007) 1.11
Severe neurotoxicity following ingestion of tetraethyl lead. J Med Toxicol (2010) 1.08
Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Technol (2010) 1.07
Infection surveillance and control programs in the Department of Veterans Affairs nursing home care units: a preliminary assessment. Am J Infect Control (2006) 1.07
Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res (2008) 1.04
In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res (2004) 1.04
Prevalence of nursing home-associated infections in the Department of Veterans Affairs nursing home care units. Am J Infect Control (2008) 1.04
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology (2013) 1.03